Reliq Health Technologies Inc.

Expert Comments:

Expert Says Health Tech Co. Still in Good Spot To Buy (11/28/22) read more >
Clive Maund, CliveMaund.com (11/22/22) "Reliq Health Technologies Inc. still looks good here and in fact is at another Buy spot as it is starting to break out of a completing bull flag that has formed over the past couple of weeks. . .a breakout from the flag should lead to a rally of similar magnitude to the one preceding the flag. . .this is a good point to add to positions or make fresh purchases."
Nine Stocks Expert Says Should Pique Your Interest (11/9/22) read more >
Telemedicine Co. Surges on Revenue News (11/4/22) read more >
	Douglas Loe, Leede Jones Gable (11/4/22) "Ontario-based Reliq Health Technologies Inc. is sustainably adding new clients for its iUGO Care platform in recent months, and just this morning added 50 new nursing home clients in Florida to its network, adding 5,000 patients per month (and so 60,000 patients per year) to its client base. . .the company will provide transitional care management to newly discharged patients at a rate of $60/month and remote health monitoring at a slightly higher rate of $65/month thereafter, at 75% gross margin."
Clive Maund, CliveMaund.com (11/1/22) "With the dip of recent days presenting us with a better entry point for Reliq Health Technologies Inc., this looks like a good time to buy. There is a clear line of support at CA$0.50, so a good point to place stops would be at about CA$0.485."
Telemedicine Co. Says It's Set To Thrive in Post-Pandemic World (9/21/22) The pandemic changed the way many people get their basic healthcare, giving a big opening to telemedicine companies like Reliq Health Technologies Inc. read more >
Jefferson Research (7/14/22) "Reliq Health Technologies Inc. is showing strong earnings quality and cash flow quality, and valuation suggests a lower amount of price risk. . .with a reported net income of -$800K in Q3/22 that was equal to the adjusted number, the company's quality of net income earnings is extremely high. In addition, operating cash flow increased during Q3/22 to -$1.5M from -$2.8M."
Healthcare Tech Firm Improves Earnings and Cash Flow in Q3/22 (6/14/22) read more >
Jefferson Research (6/10/22) "Reliq Health Technologies Inc. is showing strong earnings quality and cash flow quality. . .with a reported net income of -$800,000 in Q3/22 that was equal to the adjusted number, the company's quality of net income earnings is extremely high. In addition, operating cash flow increased during Q3/22 to -$1.5M from -$2.8M."
Clive Maund, CliveMaund.com (4/26/22) "Reliq Health Technologies Inc. is rated an Immediate Buy here. It is down on support at the second low of what is believed to be [a] double bottom that formed following a quite heavy selloff."

More Expert Comments

Clive Maund, CliveMaund.com (8/29/21) "Developments led to a sharp breakout of Reliq Health Technologies Inc.'s stock late in July, which marked the start of the current vigorous uptrend. This move is probably targeting the CA$1.30–1.40 area. . .a likely scenario is that it stops to consolidate within the channel after last week's sharp gains before proceeding towards the target."

Clive Maund, CliveMaund.com (1/8/21) "After surging to a peak at C$0.55 over a week ago, we have seen a normal reaction back by Reliq Health Technologies Inc. on declining volume. Two days ago a bullish hammerlike candle appeared on the chart with the Accumulation line holding up nicely, which alerts us to this correction having probably run its course. The slight drop today on very low volume is interpreted as a sign that it is ready to turn higher again now or very soon, and it is therefore rated an immediate buy."

Experts Following This Company

	Douglas Loe, Managing Director & Analyst, Healthcare and Biotechnology – Leede Jones Gable
Clive Maund – CliveMaund.com

The information provided above is from analysts, newsletters, the company and other contributors.

Reliq Health Technologies Inc. is a former billboard advertiser of Streetwise Reports. The company's advertising fees paid for Streetwise Reports to create this "Investor Summary Page," to which links were placed on Streetwise Reports' websites and newsletters. Streetwise Reports did not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here. Publications excerpted above may receive payment or sponsorship from the company mentioned.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.